Dendreon Corp. made history on Thursday, securing a long sought-after FDA approval for prostate cancer vaccine Provenge (sipuleucel-T). (BioWorld Today)

Human Genome Sciences Inc. got a double dose of bad news last week as partner Novartis AG withdrew its European marketing application for hepatitis C drug Zalbin (albinterferon alfa-2b) and lupus drug Benlysta (belimumab) turned up mixed results in a long-term analysis from a Phase III trial.

Four months after delivering mixed Phase III data on diabetic macular edema drug Iluvien, Alimera Sciences Inc. raised $72.1 million in its initial public offering. (BioWorld Today)

Foundation Medicine Inc. is expected to announce Thursday that it has raised $25 million in Series A financing from Third Rock Ventures to begin the arduous process of bringing cancer genome analyses to the masses. (BioWorld Today)